Safety and Efficacy of Emixustat in Stargardt Disease (NCT03772665) | Clinical Trial Compass
CompletedPhase 3
Safety and Efficacy of Emixustat in Stargardt Disease
United States194 participantsStarted 2019-01-07
Plain-language summary
The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease.
Funding Source -- FDA OOPD
Who can participate
Age range16 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* A clinical diagnosis of macular atrophy secondary to Stargardt disease (STGD)
* Macular atrophy measured to fall within a defined size range
* Two mutations of the ABCA4 gene. If only one mutation, a typical STGD appearance of the retina.
* Visual acuity in the study eye of at least 20/320
Exclusion Criteria:
* Macular atrophy secondary to a disease other than STGD
* Mutations of genes, other than ABCA4, that are associated with retinal degeneration
* Surgery in the study eye in the past 3 months
* Prior participation in a gene therapy or stem cell clinical trial for STGD
* Recent participation in a clinical trial for STGD evaluating a complement inhibitor or vitamin A derivative
* Use of certain medications in the past 4 weeks that might interfere with emixustat
* An abnormal electrocardiogram (ECG)
* Certain abnormalities on laboratory blood testing
* Female subjects who are pregnant or nursing
What they're measuring
1
Mean Rate of Change in Total Area of Macular Atrophy, as Measured by Fundus Autofluorescence (FAF)